Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | ITPR3 | Q14573 | 8/20 | 0.41 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.41 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.41 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.40 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582671 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL30240916 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL1065994 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL23563168 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL14437195 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL23563167 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL5523617 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8581971 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL14268493 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL9300366 | 0.98 | ITPR3 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103509837-B | A kind of enzyme process composite chemical legal system is for capecitabine intermediate 2 ', 3 '-two-O-ethanoyl-5 'the method of-deoxidation-5-fluorine cytidine | ZHANG JINRONG (CN) | 2016-03-09 | — | — | CN | claimed |
| CN-103509837-A | Method for preparing capecitabine intermediate 2', 3'-di-O-acetyl-5'-deoxy-5-fluorocytidine by enzymatic composite chemical method | ZHANG JINRONG | 2014-01-15 | — | — | CN | claimed |
| WO-2023060230-A2 | ENGINEERED HUMAN THYMIDINE PHOSPHORYLASE AND PHARMACOLOGICAL PREPARATIONS THEREOF | AEGLEA BIOTHERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-112876526-A | Preparation method of capecitabine key intermediate | 山东铂源药业有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-103509837-B | A kind of enzyme process composite chemical legal system is for capecitabine intermediate 2 ', 3 '-two-O-ethanoyl-5 'the method of-deoxidation-5-fluorine cytidine | ZHANG JINRONG (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-103509837-B | A kind of enzyme process composite chemical legal system is for capecitabine intermediate 2 ', 3 '-two-O-ethanoyl-5 'the method of-deoxidation-5-fluorine cytidine | ZHANG JINRONG (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-103509837-A | Method for preparing capecitabine intermediate 2', 3'-di-O-acetyl-5'-deoxy-5-fluorocytidine by enzymatic composite chemical method | ZHANG JINRONG | 2014-01-15 | — | — | CN | disclosed |
| CN-103509837-A | Method for preparing capecitabine intermediate 2', 3'-di-O-acetyl-5'-deoxy-5-fluorocytidine by enzymatic composite chemical method | ZHANG JINRONG | 2014-01-15 | — | — | CN | disclosed |